ATP as a multi-target danger signal in the brain by Ricardo J. Rodrigues et al.
MINI REVIEW
published: 28 April 2015
doi: 10.3389/fnins.2015.00148
Frontiers in Neuroscience | www.frontiersin.org 1 April 2015 | Volume 9 | Article 148
Edited by:
Magdalena Majekova,
Slovak Academy of Sciences, Slovakia
Reviewed by:
Muzamil Ahmad,
Indian Institute of Integrative Medicine,
India
Renato Corradetti,
University of Florence, Italy
*Correspondence:
Rodrigo A. Cunha,
Center for Neuroscience and Cell
Biology, Faculty of Medicine,
University of Coimbra, Rua Larga,




This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Neuroscience
Received: 13 February 2015
Accepted: 10 April 2015
Published: 28 April 2015
Citation:
Rodrigues RJ, Tomé AR and Cunha
RA (2015) ATP as a multi-target
danger signal in the brain.
Front. Neurosci. 9:148.
doi: 10.3389/fnins.2015.00148
ATP as a multi-target danger signal in
the brain
Ricardo J. Rodrigues 1, 2, Angelo R. Tomé 1, 3 and Rodrigo A. Cunha 1, 4*
1CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal, 2 Institute for Interdisciplinary
Research, University of Coimbra, Coimbra, Portugal, 3Department of Life Sciences, Faculty of Sciences and Technology,
University of Coimbra, Coimbra, Portugal, 4 Faculty of Medicine, University of Coimbra, Coimbra, Portugal
ATP is released in an activity-dependent manner from different cell types in the brain,
fulfilling different roles as a neurotransmitter, neuromodulator, in astrocyte-to-neuron
communication, propagating astrocytic responses and formatting microglia responses.
This involves the activation of different ATP P2 receptors (P2R) as well as adenosine
receptors upon extracellular ATP catabolism by ecto-nucleotidases. Notably, brain
noxious stimuli trigger a sustained increase of extracellular ATP, which plays a key role
as danger signal in the brain. This involves a combined action of extracellular ATP in
different cell types, namely increasing the susceptibility of neurons to damage, promoting
astrogliosis and recruiting and formatting microglia to mount neuroinflammatory
responses. Such actions involve the activation of different receptors, as heralded by
neuroprotective effects resulting from blockade mainly of P2X7R, P2Y1R and adenosine
A2A receptors (A2AR), which hierarchy, cooperation and/or redundancy is still not
resolved. These pleiotropic functions of ATP as a danger signal in brain damage prompt
a therapeutic interest to multi-target different purinergic receptors to provide maximal
opportunities for neuroprotection.
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Introduction
Intracellular adenosine 5′-triphosphate (ATP) plays several pivotal roles, namely in energy transfer
(Lipmann, 1941). Hence, the proposal by Burnstock (1972) that ATP was released to function as
an extracellular signal was controversial. However, this concept is supported by the identification
of mechanisms of ATP release, of ecto-enzymes metabolizing ATP named ecto-nucleotidases,
and of purinergic receptors. ATP can trigger biological effects per se through the activation of
P2 receptors (P2R) or through its ecto-nucleotidase metabolites ADP activating some P2R and
adenosine through P1R activation (Ralevic and Burnstock, 1998). Cloning identified seven P2XR
subunits P2X1-7, forming functional homomeric or heteromeric ionotropic receptors activated by
ATP (Khakh and North, 2012) and eight different metabotropic P2YR (P2Y1,2,4,6,11,12,13,14)
exhibiting a different sensitivity to ATP (P2Y11), ADP (P2Y1,12,13), UTP/ATP (P2Y2,4), UDP
(P2Y6), or UDP-glucose (P2Y14) (Abbracchio et al., 2006), whereas adenosine P1R family
comprises A1, A2A, A2B, and A3 metabotropic receptors, identified by convergent molecular,
biochemical and pharmacological data (Fredholm et al., 2011).
ATP is stored in synaptic and in astrocyte vesicles, but it can be released from
different cell types, namely nerve terminals, dendrites, and axons from neurons
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(Pankratov et al., 2006; Fields, 2011), astrocytes (Koizumi,
2010) and microglia (Imura et al., 2013; George et al., 2015)
through multiple pathways (Bodin and Burnstock, 2001). Also,
purinergic receptors display a widespread brain expression both
in neuronal or non-neuronal cells such as astrocytes, microglia
or endothelial cells (Fredholm et al., 2005; Fields and Burnstock,
2006). Accordingly, multiple roles have been attributed to
extracellular ATP. ATP can act as a neurotransmitter, since
P2XR-mediated ATPergic transmission has been found in central
synapses (Edwards et al., 1992; Bardoni et al., 1997; Nieber
et al., 1997; Pankratov et al., 1998, 2002; Mori et al., 2001).
ATP is also a controller of inflammation (Idzko et al., 2014),
with multiple actions on microglia (Koizumi et al., 2013) and
its consequences on astrocytes and neurons. ATP and adenosine
both regulate oligodendrocyte differentiation and myelination
(Agresti et al., 2005; Rivkees and Wendler, 2011) in an activity-
dependent manner (Fields, 2006). Moreover, purines modulate
astrocytic function and sustain Ca2+-waves, the substrate of
glial excitability and intercellular communication (Guthrie et al.,
1999; Koizumi, 2010) to influence synaptic activity (Zhang et al.,
2003; Jourdain et al., 2007; Franke et al., 2012). In fact, it is
mostly concluded that ATP acts as a synaptic neuromodulator
through presynaptic regulation of neurotransmitter release, by
postsynaptic regulation of other receptors or of intrinsic neuronal
excitability, with an impact in synaptic plasticity (Cunha and
Ribeiro, 2000; Khakh, 2001; Halassa et al., 2009).
The variety of purinergic receptors and their widespread
region- and cell-specific expression pattern and actions places
purinergic signaling as a major system for integration of
functional activity between neurons, glial and vascular cells in
the brain as heralded by the role of purines (ATP and adenosine)
in neuron-neuron, astrocyte-neuron, oligodendrocyte-neuron
and/or microglia/neuron bi-directional communication (Fields
and Burnstock, 2006; Butt, 2011). Moreover, the different
sensitivities of the different receptors to their different ligands
(ATP, ADP, adenosine) displaying spatial and temporal fine-
tuned gradients (Zhang et al., 2003; Cunha, 2008), endows
purinergic signaling with unique features adapted to control
brain networks. Not surprisingly, the dysfunction of this
purinergic system is closely associated with brain disorders and
we will now exploit the concept that ATP acts as a danger signal,
implying an abnormal and sustained elevation of extracellular
ATP levels in brain dysfunction and the involvement of purine
receptors, namely P2X7R (ATP), P2Y1R (ADP) and A2AR
(adenosine), in brain damage.
Sustained Increase of Extracellular ATP
Levels in Brain Pathology
There is growing evidence for a rapid increase of the extracellular
ATP levels upon noxious brain conditions such as trauma
(Wang et al., 2004; Davalos et al., 2005; Franke et al., 2006;
Choo et al., 2013), hypoxia/ischemia (Lutz and Kabler, 1997;
Jurányi et al., 1999; Melani et al., 2005) or epilepsy-associated
seizures (Wieraszko et al., 1989; see Dale and Frenguelli, 2009).
The sustained nature of the enhanced extracellular levels of
purines (ATP and adenosine) in brain dysfunction is indicative
of regulated mechanisms of ATP release rather than simple ATP
leakage. However, neither the cellular source nor the mechanism
of ATP release upon noxious brain conditions has yet been
clarified. Neurons can release ATP either through a vesicular
release (White, 1977; Pankratov et al., 2006) mostly occurring
at high frequency of firing (Wieraszko et al., 1989; Cunha et al.,
1996a) or upon anoxic or spreading depolarization (Frenguelli
et al., 2007). Astrocytes (Florian et al., 2011; Bennett et al., 2012)
and microglia (Kim et al., 2007; Sanz et al., 2009) can also
release purines upon brain dysfunction through vesicular release
(Coco et al., 2003; Bowser and Khakh, 2007; Imura et al., 2013)
and/or other mechanisms namely pannexin and/or connexin
channels (Bao et al., 2004; Reigada et al., 2008; Iwabuchi and
Kawahara, 2011), which have been proposed as a target for
neuroprotection (Shestopalov and Slepak, 2014). In other cells,
ATP release through lysosomal-dependent vesicles (Zhang et al.,
2007) and/or from pannexin channels (Bennett et al., 2012) from
autophagic (Wang et al., 2013) or apoptotic cells (Sandilos et al.,
2012; Xiao et al., 2012) acts as a find-me signal (Elliott et al., 2009)
(Figure 1).
Purinergic Receptors in Brain Pathology
The concept of ATP as a danger signal implies the release
of ATP but also the involvement of purinergic receptors in
brain disorders, which has mostly been documented for P2X7R,
P2Y1R, and A2AR.
P2X7 Receptor
P2X7R have a lower affinity for ATP (0.1–1mM) compared to
other P2XR (EC50 = 1–10µM) (Surprenant and North, 2009),
suggesting that their activation mostly occurs in pathological
conditions associated to enhanced extracellular ATP levels. This
is supported by the well-documented increase of P2X7R levels
and P2X7R gain-of-function to control different brain disorders,
from trauma or metabolic stress (Cavaliere et al., 2004; Franke
et al., 2004; Melani et al., 2006; Arbeloa et al., 2012; Kimbler
et al., 2012) to Alzheimer’s disease (AD; Parvathenani et al., 2003;
McLarnon et al., 2006; Díaz-Hernández et al., 2012;Murphy et al.,
2012), Parkinson’s disease (PD; Marcellino et al., 2010; Carmo
et al., 2014a), Huntington’s disease (HD; Díaz-Hernández et al.,
2009) epilepsy (Solle et al., 2001; Vianna et al., 2002; Rappold
et al., 2006; Avignone et al., 2008; Doná et al., 2009; Engel et al.,
2012; Jimenez-Pacheco et al., 2013), prion disease (Takenouchi
et al., 2007), and multiple sclerosis (MS, Matute et al., 2007;
Sharp et al., 2008; Grygorowicz et al., 2011). Increased P2X7R
levels have been also reported in human brain tissue of patients
with temporal lobe epilepsy (Fernandes et al., 2009; Padrão et al.,
2011), MS or AD (Narcisse et al., 2005; McLarnon et al., 2006;
Yiangou et al., 2006).
P2X7R up-regulation has been mainly associated with
microgliosis, since P2X7R promote neuronal death through
microglia-derived interleukin-1β (IL-1β) (Ferrari et al., 1996;
Chakfe et al., 2002; Skaper et al., 2006; Bernardino et al., 2008;
Takenouchi et al., 2009) or production of reactive oxygen species
(Parvathenani et al., 2003; Skaper et al., 2006; Lee et al., 2011). In
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FIGURE 1 | Integrated view of the purinergic signaling in brain
disorders. In addition to the leakage of ATP through damaged cell
membrane from injured or dying cells, evolution has assured multiple
mechanisms from different sources to place ATP in the extracellular milieu as
a danger signal in the brain. Interestingly, this increase is self-sustained:
activation of P2X7R induces the release of ATP either directly through its
channel or by exocytotic or non-exocytotic mechanisms (e.g., hemichannels);
P2Y1R induces the release of ATP from astrocytes; A2AR controls the release
of ATP from microglia and presynaptic terminals. Once in the extracellular
millieu, ATP seems to contribute to neurotoxicity through an integrated action
through P2X7R, P2Y1R, and A2AR. P2X7R: it is well-established that P2X7R
antagonism is beneficial by preventing the neurotoxic processing and release
of IL-1β from microglia; yet a deleterious action through astrocytes namely
through the regulation of glutamate levels or pro-inflammatory cytokines, or a
direct neurotoxic action cannot be discarded. P2Y1R: the contribution of
P2Y1R to brain demises has been mainly associated to astrocytic reactivity
through Ca2+-waves and through an astrocytic-driven release of glutamate;
this may be further promoted by direct actions on neuronal and synaptic
function. A2AR: there is gain of function of A2AR particularly targeted to
synapses in different brain disorders, where A2AR either with a presynaptic or
postsynaptic locus of action, has been associated to synaptic
dysfunction/loss; the precise mechanisms remain to be identified.
AD, P2X7R are predominantly up-regulated in microglia around
β-amyloid (Aβ) plaques in mice (Parvathenani et al., 2003; Lee
et al., 2011) and humans (McLarnon et al., 2006) and Aβ triggers
IL-1β secretion from microglia in a P2X7R-dependent manner
(Sanz et al., 2009). A similar gain of function of P2X7R in
formatting microglia responsiveness has been observed after
ischemia (Franke et al., 2004), MS (Yiangou et al., 2006), prion
disease (Takenouchi et al., 2007), PD (Marcellino et al., 2010)
or upon status epilepticus (Rappold et al., 2006; Avignone et al.,
2008; Kim et al., 2009; Choi et al., 2012; Engel et al., 2012), where
P2X7R blockade/deletion reduces seizure severity during status
epilepticus (Solle et al., 2001; Engel et al., 2012; Jimenez-Pacheco
et al., 2013). P2X7R have also been linked to psychiatric disorders,
as heralded by the association of P2X7R polymorphisms with
major depression (Lucae et al., 2006; Hejjas et al., 2009) and by the
anti-depressive behavior of P2X7R KO mice (Basso et al., 2009;
Csölle et al., 2013), in line with the ability of IL-1β to induce
depression-like behavioral changes (Pollak and Yirmiya, 2002;
Anisman et al., 2005).
Besides this major role on overactivation of microglia, P2X7R
are also up-regulated in reactive astrocytes and in neurons
in the diseased brain (Franke et al., 2004; Doná et al., 2009;
Engel et al., 2012). Astrocytic and neuronal P2X7R may also
contribute to neuronal damage by inducing the release of
glutamate and GABA from astrocytes (Wang et al., 2002; Duan
et al., 2003; Fu et al., 2013) or from neurons (Wirkner et al.,
2005; Marcoli et al., 2008; Cho et al., 2010; Cervetto et al., 2012),
unbalancing excitability (Tian et al., 2005) and/or causing a direct
neurotoxicity (Volonté et al., 2003) involving either the dilation
of P2X7R pore (Di Virgilio et al., 1998; Khadra et al., 2013) or the
recruitment of pannexin-1 hemichannels (Suadicani et al., 2012).
Accordingly neuronal P2X7R are required for neurotoxicity in
HD (Díaz-Hernández et al., 2009), PD (Carmo et al., 2014a)
or ischemic conditions (Arbeloa et al., 2012). A direct toxic
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action of ATP through P2X7R activation has also been shown in
oligodendrocytes (Matute et al., 2007), which may be relevant to
the contribution of P2X7R to MS (Amadio et al., 2011).
In summary, the observed gain of function of P2X7R in
pathological conditions, suggests that P2X7R may essentially
act as a danger sensor shared by different brain disorders,
contributing to the progression of brain diseases through a
combined neurotoxic overactivation of microglia, also involving
astrocytic-mediated or direct neurotoxic actions (Figures 1, 2).
P2Y1 Receptor
P2Y1R is a metabotropic receptor preferentially activated
by ADP, which pharmacological or genetic blockade affords
neuroprotection in ischemic conditions (Sun et al., 2008;
Kuboyama et al., 2011; Chin et al., 2013; Carmo et al., 2014b)
or trauma (Choo et al., 2013). P2Y1R have a widespread cellular
distribution and modulate neurons (Bowser and Khakh, 2004;
Guzman et al., 2010), astrocytes (Fam et al., 2003; Fumagalli
et al., 2003; Zheng et al., 2013) and microglia (Boucsein et al.,
2003; Ballerini et al., 2005; Bianco et al., 2005). However, the
pathological role of P2Y1R has been predominantly associated
to reactive astrocytes since P2Y1R play a key role in entraining
the propagation of calcium waves throughout the astrocyte
network (Fam et al., 2003; Neary et al., 2003; Bowser and Khakh,
2007) and promote astrocytic hyperactivity and astrogliosis upon
mechanical injury (Franke et al., 2001), ischemic conditions
(Sun et al., 2008) or AD (Delekate et al., 2014), which is
known to interfere with neuronal repair and regeneration
(McKeon et al., 1999; Tian et al., 2006). The neuroprotection
resulting from P2Y1R blockade might also involve the ability
of P2Y1R to control GABA uptake (Jacob et al., 2014) and
glutamate release (Domercq et al., 2006) impacting on synaptic
function (Jourdain et al., 2007; Santello et al., 2011), and to
regulate inflammatory/trophic factors expression in astrocytes
(Kuboyama et al., 2011). However, in line with the existence
of multiple populations of P2Y1R with different functions in
astrocytes operating different transducing pathways (Fam et al.,
2003; Sun et al., 2008; Kuboyama et al., 2011; Zheng et al.,
FIGURE 2 | Schematic diagram of the actions of P2X7R, P2Y1R
and A2AR in brain pathologies. Extracellular ATP, both directly
through the activation of P2X7R and indirectly through the activation of
P2Y1R and A2AR upon its extracellular catabolism into ADP and
adenosine, seems to be a key signal in brain pathologies, being
endowed with the unique capacity to promote and integrate
neuroinflammation, reactive astrogliosis, synaptic dysfunction/loss, and
increased susceptibility of neurons to damage. Here, it is summarized
the different mechanisms reported for each receptor that are or may be
contributing to neurodegeneration. The knowledge of the precise
mechanisms and the challenging characterization of the temporal and
spatial hierarchy of these different actions, perhaps as a common
neurodegenerative pathway to different brain disorders, will most likely
unravel an opportunity for multi-drug target therapeutics.
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2013), the blockade or the stimulation of P2Y1R in astrocytes
can cause paradoxical effects; thus, the exogenous overactivation
of P2Y1R can prevent astrocytic damage (Shinozaki et al., 2006)
and protect against neuronal damage induced by oxidative
stress through IL-6 release (Fujita et al., 2009). This apparently
paradoxical effect might also result from the up-regulation of
P2Y1R in pathological conditions, such as epilepsy (Fernandes
et al., 2009; Padrão et al., 2011), mechanical injury (Franke
et al., 2004), ischemia (Kuboyama et al., 2011) or AD (Moore
et al., 2000), which might trigger a time-dependent gain
of noxious function of P2Y1R under non-acute pathological
conditions.
Neuronal P2Y1R may also directly affect brain function and
damage (Carmo et al., 2014b). P2Y1R are located in central
synapses, where they control glutamate release (Mendonza-
Fernández et al., 2000; Rodrigues et al., 2005) and NMDA
receptors (Luthardt et al., 2003). P2Y1R also control calcium
and potassium conductances (Gerevich et al., 2004; Filippov
et al., 2006; Coppi et al., 2012) and inhibitory transmission
(Bowser and Khakh, 2004; Kawamura et al., 2004), but it is
unclear how these different effects impact on the functioning
and viability of neuronal networks; in fact, brain insults trigger
an up-regulation of neuronal P2Y1R (Moore et al., 2000)
coupled to a noxious gain of function, as heralded by the
selective ability of P2Y1R to inhibit cortical LTD only in
hypoxic conditions (Guzman et al., 2010) and to normalize
neurotransmission upon anoxic depolarization (Traini et al.,
2011). Finally, microglia P2Y1R are also expected to be
involved in the neuroprotection associated with P2Y1R blockade
since P2Y1R modulate neuroinflammatory responses (Ballerini
et al., 2005). Thus, the role of P2Y1R in neurodegeneration
is likely to involve a trans-cellular network, as illustrated by
the evidence that activated microglia is capable to modulate
synaptic function through ATP release, which in turn stimulates
astrocytic P2Y1R controlling glutamatergic gliotransmission that
feeds-back to impact on synaptic activity (Pascual et al., 2012)
(Figures 1, 2).
In summary, it seems that, in addition to P2X7R, P2Y1R also
contribute to brain dysfunction and damage, further arguing
for the role of extracellular ATP as a danger signal in brain
pathology. This is further heralded by the neurotoxicity of
exogenously added ATP (Ryu et al., 2002; Amadio et al., 2005;
Resta et al., 2005) and by the neuroprotection afforded by
non-selective P2R antagonists (Krügel et al., 2001; Lämmer
et al., 2006), supporting that P2R might be valuable targets
for neuroprotection (Volonté et al., 2003; Franke et al.,
2006).
A2A Receptor
Apart from a direct effect of ATP acting through P2X7R and
P2Y1R, ATP may also impact on brain dysfunction upon its
extracellular catabolism by ecto-nucleotidases (Cunha, 2001;
Zimmermann et al., 2012) into adenosine, followed by activation
of adenosine receptors (Cunha, 2005; Chen et al., 2007, 2013;
Gomes et al., 2011). In fact, there is robust evidence showing
that the pharmacological or genetic deletion of adenosine
A2A receptors (A2AR) diminishes neurodegeneration and brain
dysfunction in animal models of aging (Prediger et al., 2005),
PD (Schwarzschild et al., 2006), AD (Canas et al., 2009; Laurent
et al., 2014), epilepsy (El Yacoubi et al., 2008, 2009; Cognato
et al., 2010), Machado-Joseph’s disease (Gonçalves et al., 2013),
chronic stress (Batalha et al., 2013) or ADHD (Pires et al.,
2009; Pandolfo et al., 2013). This remarkably agrees with the
impact of the regular consumption of the non-selective A2AR
antagonist, caffeine, on age and AD-related memory impairment
(Cunha and Agostinho, 2010), PD (Ascherio et al., 2003), and
major depression (Lucas et al., 2011). The observation that
A2AR are mostly located in synapses (Rebola et al., 2005a),
A2AR selectively control NMDA receptor (Rebola et al., 2008)
and synaptic plasticity phenomena (d’Alcantara et al., 2001;
Costenla et al., 2011) and the deletion of neuronal A2AR is
sufficient to afford neuroprotection (Kachroo et al., 2005; Shen
et al., 2008; Wei et al., 2014), prompts the hypothesis that the
control of synaptotoxicity is at the core of A2AR neuroprotection
(Cunha and Agostinho, 2010). However, the possible role of
A2AR in astrocytes (Matos et al., 2012a, 2015; Orr et al., 2015)
and in microglia (Orr et al., 2009; Rebola et al., 2011; Gomes
et al., 2013) still remains to be determined, especially since
A2AR undergo a marked up-regulation in neurodegenerative and
neuropsychiatric disorders in glial cells (Yu et al., 2008; Matos
et al., 2012b) but mainly in synapses (Rebola et al., 2005b; Cunha
et al., 2006; Duarte et al., 2012), which is associated with a shift of
function of A2AR (reviewed in Cunha et al., 2008; Rial et al., 2014)
(Figures 1, 2).
Notably, it has been established that the adenosine
activating A2AR is derived from the activity of ecto-5′-
nucleotidase (Cunha et al., 1996b; Rebola et al., 2008;
Augusto et al., 2013), the final step in the ATP catabolism
into adenosine. Furthermore, unpublished work from
our group has documented that the blockade of ecto-5′-
nucleotidase or of A2AR affords comparable neuroprotection,
further heralding the concept that A2AR activation is part




The sustained increase of extracellular ATP levels upon brain
dysfunction/damage together with the compelling evidence that
the pharmacological blockade or genetic deletion of P2X7R or
P2Y1R or A2AR prevents or attenuates neuronal injury or the
onset/evolution of brain diseases, supports a role for ATP both
as a warning and harmful signal in the brain. It will now
be important to understand the time-dependent involvement
of these three purinoceptors and their inter-play. In fact, the
activation of A2AR or P2X7R may constitute an auto-stimulatory
loop (Verderio and Matteoli, 2001; Cunha et al., 2012) since they
can trigger ATP release from astrocytes, neurons or microglia
(George et al., 2015), either directly through the P2X7R pore
(Duan and Neary, 2006), through interaction with pannexin
channels (Locovei et al., 2007; Iglesias et al., 2008; Bennett et al.,
2012), or by exocytotic release (Gutiérrez-Martín et al., 2011).
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Furthermore, P2X7R synergistically regulate P2Y1R activation
(Locovei et al., 2006), particularly in pathological conditions
(Traini et al., 2011; Vessey et al., 2011; Choo et al., 2013). Finally,
emerging evidence indicates a synergic interplay between ATP
and its metabolite adenosine (Gerwins and Fredholm, 1992;
Neary et al., 1998; Chevrier et al., 2006; Färber et al., 2008;
Koizumi et al., 2013; George et al., 2015), namely between
A2AR and P2X7R (Chen et al., 2004; Pellegatti et al., 2011)
and P2Y1R (Stafford et al., 2007; Doengi et al., 2008; Suzuki
et al., 2011), which highlights the possible key role of ecto-
nucleotides in regulating the integration of purinergic responses.
Thus, the action of individual purinergic receptors may be part
of a time-dependent orchestrated response triggered by the
increase of extracellular ATP levels in brain pathology (Figure 2).
The understanding of the hierarchy and integration/redundancy
of their actions will be paramount to develop multi-target
therapeutics to exploit this role of ATP as a danger signal in the
brain.
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